NCT02856451View on ClinicalTrials.gov

Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

CompletedOBSERVATIONAL
Enrollment

486

Participants

Timeline

Start Date

December 9, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Encephalitis
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (1)

08540

Local Institution, Princeton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY